Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01243619 · ClinicalTrials.gov registry record · NA
FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT01243619 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 5 participants.
The verdict
NCT01243619, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to develop a more advanced software program that will collect, compare and analyze tumor images for evaluation. Another purpose of this study is to learn if a new radio-tracer for tumor imaging called 3'-deoxy-3'(18) F-fluorothymidine (FLT) can improve the evaluation of tumors during a PET/CT scan. This new type of image tracking is meant to improve the visualization of tumor active and size.
Interventions
- DRUG 3'-deoxy-3'-(18) F-fluorothymidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01243619
The ClinicalTrials.gov registry entry for NCT01243619 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 3'-deoxy-3'-(18) F-fluorothymidine is the first listed.
NCT01243619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01243619 about?
NCT01243619 is a clinical study titled "FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer". The purpose of this pilot study is to develop a more advanced software program that will collect, compare and analyze tumor images for evaluation. Another purpose of this study is to learn if a new radio-tracer for tumor imaging called 3'-deoxy-3'(18) F-fluorothymidine (FLT) can improve the evaluati...
What is the current status of trial NCT01243619?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2010-08. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01243619?
The interventions under investigation include: 3'-deoxy-3'-(18) F-fluorothymidine (DRUG).
Who is sponsoring clinical trial NCT01243619?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.